Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial.
Johnson & Johnson Announces Submission to World Health Organization for Emergency Use Listing of investigational single-shot Janssen COVID-19 vaccine candidate
February 22, 2021
Related blog posts
Search for COVID-19 drugs boosted by SARS discovery
August 27, 2020